ConductScience.org, home

Comparison · NCT02509481-473a3919

Single MDA vs Repeated MDA: Number of 6-10 Year Old Participants With Soil Transmitted Helminths (STH)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Single MDA vs Repeated MDA: Number of 6-10 Year Old Participants With Soil Transmitted Helminths (STH). Trial comparisons, record NCT02509481-473a3919. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02509481-473a3919

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02460.00840.0698wilson
Risk in group 2000.0337wilson
Risk difference, group 1 minus group 20.0246-0.01280.0698newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to treat, for one more participant with the outcome on Single MDA than on Repeated MDA40.7from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Single MDA
Single mass drug administration of ivermectin (150 µg/kg) + albendazole (400 mg) performed after the start of the rainy season as part of public health efforts to eliminate lymphatic filariasis.~Ivermectin~Albendazole
3122OG000
Group 2Repeated MDASame as Active Comparator, but then followed by five more mass drug administrations of ivermectin only (150 µg/kg) every three weeks thereafter.~Ivermectin~Albendazole0110OG001

Outcome

Type
SECONDARY
Title
Number of 6-10 Year Old Participants With Soil Transmitted Helminths (STH)
Description
Prevalence of soil transmitted helminth infections in children between 6-10 years old from the beginning to the end of the intervention
Time frame
Approximately 20 weeks, from before the start of the first MDA to 4 weeks following the last MDA in the Experimental arm
Population
This outcome was only measured in older enrolled children between 6-10 years of age, who were not in our primary outcome cohort, and who were eligible to be treated with ivermectin due to their height \>90 cm (232 of 2712 participants).

Source ClinicalTrials.gov

Trial

Title
Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study
NCT number
NCT02509481
Phases
PHASE2, PHASE3
Conditions
Malaria, Lymphatic Filariasis
Interventions
Ivermectin, Albendazole
Lead sponsor
Colorado State University
Results first posted
2019-01-04

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02509481-473a3919